BPA 2012: Genzyme, Organogenesis, & Alkermes CEOs Will Discuss: Could We Do It Again Today?
Don’t miss Thursday’s Keynote Panel at BioPharm America 2012! Join David Meeker, Geoff MacKay, Richard Pops, and Moderator Karen Bernstein, Co-Founder and Chairman of BioCentury, as they discuss:
From start-up to commercial company and the challenges in between: Could we do it again today?
“We are all aware of the challenges present in today’s drug development environment. R&D budgets are scaled back, financing is tight, the regulatory pathway is as uncertain as ever, and the road to yesterday’s blockbusters is a long and arduous one. The one constant amid all of these changes is that drug development remains a highly collaborative process,” said Geoff MacKay, CEO of Organogenesis.
“The landscape for biopharma companies is changing with new laws and a greater focus on patient needs,” said David Meeker, CEO of Genzyme, a Sanofi company. “What worked in the past to make Genzyme a global biotechnology leader based in Massachusetts, may not work today. I look forward to sharing thoughts on innovation and partnering opportunities with others at BioPharm America.“
BioPharm America is North America’s premiere partnering conference. BioPharm America brings the RIGHT people together, from all over the world, all in one place for the most effective partnering. The growing list of firms attending this year’s meeting includes: Actelion, Alkermes, Alexion, Amgen, AstraZeneca, Atlas Ventures, Biogen Idec, Bristol-Myers Squibb, Celgene, CMEA Capital, Epizyme, Genzyme, HealthCare Ventures, Ironwood, Johnson & Johnson, Merck Research Venture Fund, NovoNordisk, Sanofi Oncology, Shire HGT, Takeda, United Therapeutics, and many more of the industry’s heavy hitters and research institutions such as Children’s Hospital, Harvard, Tuft’s, and Yale.
To see the full BioPharm America 2012 program, click here.
To see all partnering information, click here.
To register for BioPharm America 2012, click here.
Posted on August 13, 2012, in MassBio, Signature Events and tagged Alkermes, BioCentury, BioPharm America 2012, BPA 2012, David Meeker, Genzyme, Geoff Mackay, Karen Bernstein, Organogenesis, Richard Pops, Sanofi. Bookmark the permalink. Leave a Comment.